IL323044A - שיטות תחזיתיות וטיפוליות לסרטן ריאות של תאים לא קטנים - Google Patents

שיטות תחזיתיות וטיפוליות לסרטן ריאות של תאים לא קטנים

Info

Publication number
IL323044A
IL323044A IL323044A IL32304425A IL323044A IL 323044 A IL323044 A IL 323044A IL 323044 A IL323044 A IL 323044A IL 32304425 A IL32304425 A IL 32304425A IL 323044 A IL323044 A IL 323044A
Authority
IL
Israel
Prior art keywords
individual
gene signature
signature score
sample
expression level
Prior art date
Application number
IL323044A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL323044A publication Critical patent/IL323044A/he

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • G01N33/5752—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
IL323044A 2023-03-06 2024-03-05 שיטות תחזיתיות וטיפוליות לסרטן ריאות של תאים לא קטנים IL323044A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363488707P 2023-03-06 2023-03-06
PCT/US2024/018472 WO2024186790A1 (en) 2023-03-06 2024-03-05 Prognostic and therapeutic methods for non-small cell lung cancer

Publications (1)

Publication Number Publication Date
IL323044A true IL323044A (he) 2025-10-01

Family

ID=90482049

Family Applications (1)

Application Number Title Priority Date Filing Date
IL323044A IL323044A (he) 2023-03-06 2024-03-05 שיטות תחזיתיות וטיפוליות לסרטן ריאות של תאים לא קטנים

Country Status (8)

Country Link
EP (1) EP4677119A1 (he)
KR (1) KR20250163916A (he)
CN (1) CN120826478A (he)
AU (1) AU2024230918A1 (he)
IL (1) IL323044A (he)
MX (1) MX2025010448A (he)
TW (1) TW202440631A (he)
WO (1) WO2024186790A1 (he)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120738345B (zh) * 2025-08-27 2025-12-16 清华大学 脑出血相关标志物pclaf基因的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100366386C (zh) 2002-02-26 2008-02-06 先进微装置公司 用于控制衬底的化学机械式抛光的方法及装置
US20040121370A1 (en) 2002-09-11 2004-06-24 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
EP1578373A4 (en) 2002-09-11 2007-10-24 Genentech Inc NEW COMPOSITIONS AND METHOD FOR THE TREATMENT OF ILLNESSES OF THE IMMUNE SYSTEM
EP2279412B1 (en) 2008-04-09 2017-07-26 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
KR20160030936A (ko) 2013-07-16 2016-03-21 제넨테크, 인크. Pd-1 축 결합 길항제 및 tigit 억제제를 사용한 암을 치료하는 방법
CA2953245A1 (en) 2014-07-16 2016-01-21 Genentech, Inc. Methods of treating cancer using tigit inhibitors and anti-cancer agents
EP3240908A2 (en) 2014-12-30 2017-11-08 F. Hoffmann-La Roche AG Methods and compositions for prognosis and treatment of cancers
DK3294770T4 (da) 2015-05-12 2024-05-21 Hoffmann La Roche Terapeutiske og diagnostiske fremgangsmåder til cancer
IL255372B (he) 2015-05-29 2022-07-01 Genentech Inc שיטות טיפוליות ואבחוניות עבור סרטן
LT3353210T (lt) 2015-09-25 2025-01-27 F. Hoffmann-La Roche Ag Antikūnai prieš tigit ir jų naudojimo būdai
AU2018251993A1 (en) * 2017-04-14 2019-10-24 Genentech, Inc. Diagnostic and therapeutic methods for cancer
MX2020008882A (es) * 2018-02-26 2021-01-08 Genentech Inc Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
EP4198057A1 (en) * 2018-12-05 2023-06-21 F. Hoffmann-La Roche AG Diagnostic methods and compositions for cancer immunotherapy
JP2023529206A (ja) * 2020-06-12 2023-07-07 ジェネンテック， インコーポレイテッド がん免疫療法のための方法及び組成物

Also Published As

Publication number Publication date
CN120826478A (zh) 2025-10-21
EP4677119A1 (en) 2026-01-14
WO2024186790A1 (en) 2024-09-12
MX2025010448A (es) 2025-10-01
TW202440631A (zh) 2024-10-16
KR20250163916A (ko) 2025-11-21
AU2024230918A1 (en) 2025-10-16

Similar Documents

Publication Publication Date Title
JP6901505B2 (ja) 全細胞がんワクチンおよびその選択のための方法
US20080234138A1 (en) TP53 gene expression and uses thereof
Amaro et al. Evidence of epidermal growth factor receptor expression in uveal melanoma: inhibition of epidermal growth factor-mediated signalling by Gefitinib and Cetuximab triggered antibody-dependent cellular cytotoxicity
CN113260633A (zh) 用于癌症免疫疗法的诊断方法和组合物
WO2014022826A2 (en) Biomarker associated with risk of melanoma reoccurrence
CN105435228A (zh) 三氧化二砷的抗肿瘤新用途及抗肿瘤制剂
JP2022179694A (ja) Ｋｒａｓバリアントがん患者の免疫ベースの処置
KR102338510B1 (ko) 항-her2 치료제에 대한 동반진단 마커 및 이의 용도
Huang et al. Colorectal cancer-specific IFNβ delivery overcomes dysfunctional dsRNA-mediated type I interferon signaling to increase the abscopal effect of radiotherapy
IL323044A (he) שיטות תחזיתיות וטיפוליות לסרטן ריאות של תאים לא קטנים
US20240398831A1 (en) Compositions comprising small molecule regulators of tumor immunity and methods of using same
Jang et al. RNA N6‐Methyladenosine‐Binding Protein YTHDFs Redundantly Attenuate Cancer Immunity by Downregulating IFN‐γ Signaling in Gastric Cancer
JP2025003730A (ja) 癌患者への免疫チェックポイント阻害薬の投与の有効性を予測するためのデータを収集する方法
CN117731781A (zh) Nat10促进剂在制备用于增强肝癌免疫治疗效果的增效剂中的应用
Wu et al. Membrane palmitoylated protein MPP1 inhibits immune escape by regulating the USP12/CCL5 axis in urothelial carcinoma
CN110974965A (zh) Atf3在制备pd-l1/pd-1单抗肿瘤免疫治疗药物中的应用
US8883155B2 (en) Methods for treating hematopoietic malignancies
US20100152136A1 (en) TP53 Gene expression and uses thereof
CN117412987A (zh) 用于癌症治疗的cd274突变
US12070444B2 (en) Modulation of molecular markers using S-equol
WO2021007503A1 (en) Targeting galectin-9 as a therapeutic strategy for t-cell exhaustion in t-cell acute lymphoblastic leukemia
CN117866906B (zh) Foxr1抑制剂在制备用于治疗肿瘤的药物中的应用
Gao et al. Elevated circASCC3 Suppresses Antitumor Immunity by Sponging miR-432-5p to Upregulate C5a in Non-small-cell Lung Cancer
US20240327520A1 (en) Methods and compositions for pkc-delta inhibition and cancer immunotherapy
US20230340607A1 (en) Compositions and methods for detecting gene fusions of rad51ap1 and dyrk4 and for diagnosing and treating cancer